in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
FDA issues warning letter to API manufacturer in Japan
10:03 AM MDT | April 5, 2013 | Deepti Ramesh
US FDA issued a warning letter late last month to the active pharmaceutical ingredient (API) manufacturing facility of Asada Milling Co. (Kanra, Japan), for deviating from cGMP. An FDA inspection of the Kanra API facility from 9–12 October 2012 identified significant deviations from cGMP for the manufacture of APIs, FDA says. The violations for the manufacture of APIs at the Kanra site include failure to perform quality-control-related activities, failure to maintain and clean manufacturing equipment and facilities, failure to establish written procedures...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee